Shares of Biohaven Ltd. (NYSE:BHVN – Get Rating) have received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $58.32.
A number of analysts have recently weighed in on the company. BTIG Research assumed coverage on Biohaven in a research report on Friday, December 2nd. They set a "buy" rating and a $24.00 price target on the stock. Piper Sandler reduced their target price on Biohaven from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Wednesday, October 26th. JPMorgan Chase & Co. assumed coverage on Biohaven in a report on Wednesday, January 4th. They set an "overweight" rating and a $23.00 price objective for the company. Cowen lowered their target price on shares of Biohaven to $25.00 in a research report on Monday, November 7th. Finally, SVB Securities assumed coverage on Biohaven in a research report on Tuesday, January 24th. They issued an "outperform" rating and a $24.00 price target on the stock.
Get Biohaven alerts:Biohaven Price Performance
Biohaven stock opened at $16.98 on Monday. The stock's 50 day moving average price is $16.26 and its 200 day moving average price is $61.73. The company has a market cap of $1.16 billion, a PE ratio of -1.22 and a beta of 1.08. Biohaven has a 1-year low of $5.54 and a 1-year high of $20.57.
Biohaven (NYSE:BHVN – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($1.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.53) by $0.78. On average, equities research analysts anticipate that Biohaven will post -9.82 EPS for the current fiscal year.Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. US Bancorp DE grew its stake in Biohaven by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company's stock valued at $70,000 after acquiring an additional 94 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Biohaven by 311.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 280 shares of the company's stock valued at $41,000 after buying an additional 212 shares during the last quarter. Cetera Advisor Networks LLC raised its holdings in Biohaven by 8.1% during the 2nd quarter. Cetera Advisor Networks LLC now owns 3,030 shares of the company's stock valued at $442,000 after buying an additional 226 shares during the last quarter. Chartwell Investment Partners LLC raised its holdings in Biohaven by 2.6% in the 2nd quarter. Chartwell Investment Partners LLC now owns 10,741 shares of the company's stock worth $1,565,000 after purchasing an additional 268 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC raised its holdings in Biohaven by 13.3% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 2,286 shares of the company's stock worth $333,000 after purchasing an additional 268 shares in the last quarter. 98.01% of the stock is owned by institutional investors.
Biohaven Company Profile
(Get Rating)
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.
Further Reading
- Get a free copy of the StockNews.com research report on Biohaven (BHVN)
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
- Wall Street Says These 3 Stocks Will Grow Earnings In 2023
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.